Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 162Myelodysplastic Syndromes 46Leukemia, Myelomonocytic, Chronic 26Leukemia 16Myeloproliferative Disorders 11Recurrence 9Hematologic Neoplasms 8Leukemia, Biphenotypic, Acute 7Primary Myelofibrosis 6Neoplasms 6Lymphoma, T-Cell, Peripheral 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Anemia, Refractory, with Excess of Blasts 5Neoplasm, Residual 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Leukemia, Monocytic, Acute 4Hematologic Diseases 4GATA2 Deficiency 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pathologic Complete Response 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Myelodysplastic-Myeloproliferative Diseases 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Sarcoma 2

Interventions

venetoclax 1ruxolitinib 1pevonedistat 1Imatinib Mesylate 1Dasatinib 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypereosinophilic Syndrome × Azacitidine × 1 year × Clear all
NCT03862157 2026-03-11

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
40 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡